Limits...
Fractalkine is expressed in the human ovary and increases progesterone biosynthesis in human luteinised granulosa cells.

Huang S, Zhao P, Yang L, Chen Y, Yan J, Duan E, Qiao J - Reprod. Biol. Endocrinol. (2011)

Bottom Line: Treatment with fractalkine augmented hCG stimulation of progesterone production in a dose-dependent manner with concomitant increases in transcript levels for key steroidogenic enzymes (StAR, 3-βHSD and CYP11A) but had no effect on estradiol biosynthesis (P<0.05).Fractalkine and CX3CR1 were found to express in human ovary and luteinising granulosa cells.Fractalkine can increase the biosynthesis of progesterone in a dose-dependent manner by enhancing transcript levels of key steroidogenic enzymes.

View Article: PubMed Central - HTML - PubMed

Affiliation: Reproductive Medical Center, Peking University Third Hospital, Beijing, People's Republic of China.

ABSTRACT

Background: Recent evidence from rodent ovaries has demonstrated expression of fractalkine and the existence of fractalkine receptor, and showed that there is a significant increase in steroidogenesis in response to fractalkine, yet the role of fractalkine and CX3CR1 in the human ovary is still unknown. This study aimed to determine the expression levels of fractalkine and CX3CR1 in the human ovary and to investigate their roles in sexual hormone biosynthesis by human luteinising granulosa cells. This is the first detailed report of fractalkine and CX3CR1 expression and function in the human ovary.

Methods: Fractalkine and CX3CR1 expression levels were measured by immunohistochemistry using ovarian tissue from pathological specimens from five individuals. Granulosa cells were obtained from patients during IVF treatment. They were cultured and treated with increasing doses of hCG with or without fractalkine. Media were collected to detect estradiol and progesterone by chemiluminescence. StAR, 3-βHSD and CYP11A expression were determined in granulosa cells treated with or without fractalkine by real-time RT-PCR.

Results: Fractalkine and CX3CR1 were expressed in the human ovary and in luteinising granulosa cells. However, fractalkine expression was stronger in luteinising granulosa cells. Treatment with fractalkine augmented hCG stimulation of progesterone production in a dose-dependent manner with concomitant increases in transcript levels for key steroidogenic enzymes (StAR, 3-βHSD and CYP11A) but had no effect on estradiol biosynthesis (P<0.05).

Conclusions: Fractalkine and CX3CR1 were found to express in human ovary and luteinising granulosa cells. Fractalkine can increase the biosynthesis of progesterone in a dose-dependent manner by enhancing transcript levels of key steroidogenic enzymes.

Show MeSH
Expression of fractalkine and CX3CR1 in the human ovary by immunohistochemistry. A Fractalkine was localised in granulosa cells in the follicular phase (arrowheads). B Fractalkine was localised in luteinised granulosa cells (arrowheads). C Negative control (the primary antibodies were replaced by PBS). D CX3CR1 was localised in granulosa cells in the follicular phase (arrowheads). E CX3CR1 was localised in luteinised granulosa cells (arrowheads). F Negative control (the primary antibodies were replaced by PBS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3141648&req=5

Figure 1: Expression of fractalkine and CX3CR1 in the human ovary by immunohistochemistry. A Fractalkine was localised in granulosa cells in the follicular phase (arrowheads). B Fractalkine was localised in luteinised granulosa cells (arrowheads). C Negative control (the primary antibodies were replaced by PBS). D CX3CR1 was localised in granulosa cells in the follicular phase (arrowheads). E CX3CR1 was localised in luteinised granulosa cells (arrowheads). F Negative control (the primary antibodies were replaced by PBS).

Mentions: Immunohistochemical analysis from pathological specimens from 5 individuals demonstrated that fractalkine was expressed in granulosa cells in the follicular phase in human ovaries. Stronger signals were detected in luteal tissues and luteinised granulosa cells. For CX3CR1 staining, comparable levels of signal were found in granulosa cells in the follicular and luteal phases. Unlike fractalkine, CX3CR1 expression did not vary in different phases of the cycle. No signal was detected in control sections when primary antibodies were replaced by PBS. (Figure 1)


Fractalkine is expressed in the human ovary and increases progesterone biosynthesis in human luteinised granulosa cells.

Huang S, Zhao P, Yang L, Chen Y, Yan J, Duan E, Qiao J - Reprod. Biol. Endocrinol. (2011)

Expression of fractalkine and CX3CR1 in the human ovary by immunohistochemistry. A Fractalkine was localised in granulosa cells in the follicular phase (arrowheads). B Fractalkine was localised in luteinised granulosa cells (arrowheads). C Negative control (the primary antibodies were replaced by PBS). D CX3CR1 was localised in granulosa cells in the follicular phase (arrowheads). E CX3CR1 was localised in luteinised granulosa cells (arrowheads). F Negative control (the primary antibodies were replaced by PBS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3141648&req=5

Figure 1: Expression of fractalkine and CX3CR1 in the human ovary by immunohistochemistry. A Fractalkine was localised in granulosa cells in the follicular phase (arrowheads). B Fractalkine was localised in luteinised granulosa cells (arrowheads). C Negative control (the primary antibodies were replaced by PBS). D CX3CR1 was localised in granulosa cells in the follicular phase (arrowheads). E CX3CR1 was localised in luteinised granulosa cells (arrowheads). F Negative control (the primary antibodies were replaced by PBS).
Mentions: Immunohistochemical analysis from pathological specimens from 5 individuals demonstrated that fractalkine was expressed in granulosa cells in the follicular phase in human ovaries. Stronger signals were detected in luteal tissues and luteinised granulosa cells. For CX3CR1 staining, comparable levels of signal were found in granulosa cells in the follicular and luteal phases. Unlike fractalkine, CX3CR1 expression did not vary in different phases of the cycle. No signal was detected in control sections when primary antibodies were replaced by PBS. (Figure 1)

Bottom Line: Treatment with fractalkine augmented hCG stimulation of progesterone production in a dose-dependent manner with concomitant increases in transcript levels for key steroidogenic enzymes (StAR, 3-βHSD and CYP11A) but had no effect on estradiol biosynthesis (P<0.05).Fractalkine and CX3CR1 were found to express in human ovary and luteinising granulosa cells.Fractalkine can increase the biosynthesis of progesterone in a dose-dependent manner by enhancing transcript levels of key steroidogenic enzymes.

View Article: PubMed Central - HTML - PubMed

Affiliation: Reproductive Medical Center, Peking University Third Hospital, Beijing, People's Republic of China.

ABSTRACT

Background: Recent evidence from rodent ovaries has demonstrated expression of fractalkine and the existence of fractalkine receptor, and showed that there is a significant increase in steroidogenesis in response to fractalkine, yet the role of fractalkine and CX3CR1 in the human ovary is still unknown. This study aimed to determine the expression levels of fractalkine and CX3CR1 in the human ovary and to investigate their roles in sexual hormone biosynthesis by human luteinising granulosa cells. This is the first detailed report of fractalkine and CX3CR1 expression and function in the human ovary.

Methods: Fractalkine and CX3CR1 expression levels were measured by immunohistochemistry using ovarian tissue from pathological specimens from five individuals. Granulosa cells were obtained from patients during IVF treatment. They were cultured and treated with increasing doses of hCG with or without fractalkine. Media were collected to detect estradiol and progesterone by chemiluminescence. StAR, 3-βHSD and CYP11A expression were determined in granulosa cells treated with or without fractalkine by real-time RT-PCR.

Results: Fractalkine and CX3CR1 were expressed in the human ovary and in luteinising granulosa cells. However, fractalkine expression was stronger in luteinising granulosa cells. Treatment with fractalkine augmented hCG stimulation of progesterone production in a dose-dependent manner with concomitant increases in transcript levels for key steroidogenic enzymes (StAR, 3-βHSD and CYP11A) but had no effect on estradiol biosynthesis (P<0.05).

Conclusions: Fractalkine and CX3CR1 were found to express in human ovary and luteinising granulosa cells. Fractalkine can increase the biosynthesis of progesterone in a dose-dependent manner by enhancing transcript levels of key steroidogenic enzymes.

Show MeSH